

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Saum B Ghodoussipour, MD

eRA COMMONS USER NAME (credential, e.g., agency login): GHODOUSSIPOUR

POSITION TITLE: Assistant Professor of Surgery

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Boston University, Boston, MA	BA	05/2008	Biology, Economics
Temple University School of Medicine, Philadelphia, PA	MD	05/2013	Medicine
Los Angeles County + USC Medical Center, Los Angeles, CA	Internship	06/2014	General Surgery
Los Angeles County + USC Medical Center, Los Angeles, CA	Residency	06/2018	Urologic Surgery
University of Southern California, USC Institute of Urology, Los Angeles, CA	Fellowship	06/2020	Urologic Oncology

A. Personal Statement

I completed a 5 year Urology residency and 2 year Society of Urologic Oncology fellowship where I received high-volume clinical training and experience caring for patients with bladder cancer. This led to my recruitment as Assistant Professor of Surgery and Director of the Bladder and Urothelial Cancer Program at the Rutgers Cancer Institute of New Jersey. My clinical understanding of bladder cancer has inspired my research goals, which are to facilitate treatment decisions for patients before and after surgery, study surgical techniques to optimize oncologic and functional outcomes and to develop and implement perioperative care pathways to enhance recovery after surgery.

B. Positions and Honors**Positions and Employment:**

2018-2020	Clinical Instructor, USC Institute of Urology, Keck School of Medicine of University of Southern California
2018-2020	Faculty Physician, Los Angeles County + USC Medical Center
2020-	Assistant Professor of Surgery, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School
2020-	Director, Bladder and Urothelial Cancer Program, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey
2021-	Chair of the Enhanced Recovery After Surgery Committee, Division of Urology, Rutgers Robert Wood Johnson Medical School

Other Experience and Professional Memberships:

2008-2009	Study Coordinator, Department of Gastroenterology, Boston Children's Hospital
2009-2010	President, Temple CARES (Community, Advocacy, Referral and Educational Services)

2010-2011 Member, Admissions Committee, Temple University School of Medicine
 2014- Member, American Urological Association
 2017-2019 Peer selected representative, USC Institute of Urology Program Evaluation Committee
 2018- Member, Society of Urologic Oncology
 2019 Selected Nominee, American Urological Association Early-Career Investigators Workshop
 2020- Faculty Advisor, Urology Interest Group, Rutgers Robert Wood Johnson Medical School
 2021- Member, American Society of Clinical Oncology
 2021- Member, Eastern Cooperative Oncology Group (ECOG) – American College of Radiology Imaging Network (ACRIN)
 2021- Member, Big Ten Cancer Research Consortium – Genitourinary Clinical Trial Working Group
 2021- Consultant, Diversity and Inclusion Steering Committee, Janssen Research & Development
 2021- Content Editor, Enhanced Recovery After Surgery Society Website, Urologic Surgery
 2021- Member, Oncology Mortality Review Committee, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital

Honors:

2008 Boston University – *cum laude*
 2010 Student Research Fellowship Award, Crohn’s and Colitis Foundation of America
 2013 Richard Kendall Award for Excellence in Urology, Temple University School of Medicine
 2015 Arnold Heyman MD Honorarium for the Western Section American Urological Association Meeting, USC Institute of Urology
 2016 Earl F. Nation Resident Scholarship, Western Section American Urological Association
 2016 Arnold Heyman MD Honorarium for the Western Section American Urological Association Meeting, USC Institute of Urology
 2017 Awardee, Committee of Interns and Residents Patient Care and Safety Grant, Los Angeles County + USC Medical Center
 2017 John P Stein Award for Integrity in Medicine, USC Institute of Urology
 2018 Best Video Presentation, Renal Oncology, American Urological Association National Meeting
 2020 Best Poster, Bladder Cancer: Basic Research and Pathophysiology, American Urological Association National Meeting
 2020 The Fellows Teaching Award, Keck School of Medicine, USC Institute of Urology
 2021 Program for Early Career Excellence, Rutgers the State University of New Jersey
 2021 Surgical Teaching Award, Rutgers Robert Wood Johnson Division of Urology
 2022 Surgical Teaching Award, Rutgers Robert Wood Johnson Division of Urology
 2023 Inductee, Society of University Surgeons

C. Contributions to Science

1. My publications document my expertise in the management of muscle invasive bladder cancer. Results from the following studies highlight the importance of surgical technique, such as extent of lymph node dissection, and the importance of modifiable (smoking) and non-modifiable patient factors during neoadjuvant therapy.
 - a. Nazemi A, **Ghodoussipour S**, Pearce S, Bhanvadia S, Daneshmand S: Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer; Urol Oncol. 2019 Oct;37(10):784-790 PMID: 31076355
 - b. Cacciamani GE, **Ghodoussipour S**, Mari A, Gill KS, Desai M, Artibani W, Gill PS, Shariat SF, Gill IS, Djaladat H: Association Between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes Following Radical Cystectomy: Systematic Review and Meta-Analysis; J Urol. 2020 Feb 27 PMID: 32105187
 - c. Nassiri N, **Ghodoussipour S**, Maas M, Nazemi A, Asanad K, Pearce S, Bhanvadia SS, Djaladat H, Schuckman A, Daneshmand S: Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. Urology. 2020 PMID: 32268173
 - d. **Ghodoussipour S**, Xu W, Tran K, Atkinson R, Cho D, Miranda G, Cai J, Bhanvadia S, Schuckman A, Daneshmand S, Djaladat H. Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response. Urol Oncol. 2020 PMID: 32900621

2. The majority of patients undergoing radical cystectomy in the United States receive incontinent urinary diversion despite being candidates for continent diversion. Much of my research has focused on exploring factors responsible for this disparity. This includes assessments of surgical factors/feasibility and evaluations of functional outcomes after continent diversion.
 - a. Loh-Doyle JC, Ashrafi A, Nazemi A, **Ghodooussipour S**, Thompson E, Wayne K, Boyd SD: Dual Prosthetic Implantation After Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors; *Urology*. 2019 May;127:127-132 PMID: 30664894
 - b. **Ghodooussipour S**, Daneshmand S: Voiding Dysfunction after Neobladder Urinary Diversion; *Curr Bladder Dysfunct Rep*. 2020
 - c. Vasantachart A, Daneshmand S, Cai J, Miranda G, **Ghodooussipour S**, Schuckman AK, Djaladat H, Ballas L. Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. *Urology*. 2020 PMID: 32979377
 - d. **Ghodooussipour S**, Ladi Seyedian SS, Jiang D, Lifton J, Ahmadi H, Wayne K, Miranda G, Cai J, Djaladat H, Schuckman A, Bhanvadia S, Daneshmand S. Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients. *BJU Int*. 2020 PMID: 33348465

3. I have interest in perioperative care pathways to improve outcomes for patients after radical cystectomy. The adoption of enhanced recovery after surgery (ERAS) protocols has improved the patient experience and decreased length of stay and costs, but significant morbidity remains, regardless of individual interventions or surgical approach. A greater understanding of modifiable factors is needed.
 - a. Thaker H, **Ghodooussipour S**, Saffarian M, Ashrafi A, Miranda G, Cai J, Schuckman AK, Aron M, Desai M, Gill IS, Daneshmand S, Djaladat H: Extended hospital stay after radical cystectomy with enhanced recovery protocol; *Can J Urol*. 2019 Feb;26(1):9654-9659 PMID: 30797248
 - b. Chen J, Djaladat H, Schuckman AK, Aron M, Desai M, Gill IS, Clifford TG, **Ghodooussipour S**, Miranda G, Cai J, Daneshmand S: Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field?; *Urol Oncol*. 2019 Oct;37(10):765-773 PMID: 31285114
 - c. **Ghodooussipour S**, Naser-Tavakolian A, Cameron B, Mitra AP, Miranda G, Cai J, Bhanvadia S, Aron M, Desai M, Gill I, Schuckman A, Daneshmand S, Djaladat H: Internal audit of an enhanced recovery after surgery protocol for radical cystectomy; *World J Urol*. 2020 Feb 28 PMID: 32112242
 - d. Cacciamani GE, Medina L, Lin-Brandt M, Tafuri A, Lee RS, **Ghodooussipour S**, Ashrafi AN, Winter M, Ahmadi N, Rajarubendra N, Miranda G, De Castro Abreu A, Berger A, Aron M, Gill IS, Desai M. Timing, Patterns and Predictors of 90-days Readmission Rate after Robotic Radical Cystectomy. *J Urol*. 2020 PMID: 33035137

Complete List of Published Work in MyBibliography (71 publications):

<https://www.ncbi.nlm.nih.gov/myncbi/saum.ghodooussipour.2/bibliography/public/>